HIV / AIDS

The mobile unit provided services to 229 clients from October 2018 to April 2019, 168 (73.7%) of whom sought PrEP.

The risk of incident DM was more substantial with INSTIs vs. NNRTIs (HR=1.22; CI: 0.95-1.57), and a similar rate was noted with PI- vs. NNRTI-initiators (HR=1.25; CI: 1.05-1.49).

A 7-year study highlights the ability of an ultra-long-acting injectable implant to elute HIV drug combinations for months at a time.

In order to overcome the barriers to HIV care, it is important for both patients and health care professionals to mutually agree that a particular strategy is useful.

The FDA has approved a pre-exposure prophylaxis (PrEP) indication for Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets; F/TAF).

Microarray patches could be key to providing a self-delivery system, that is also discreet, to administer HIV prevention and contraception to women in low-resource settings.

Awareness for HIV PrEP was high for all racial and ethnic groups, but black and Hispanic MSM discussed its use with physicians less often than white counterparts.

As September draws to a close, the Contagion® editorial team is recapping the trends and top infectious disease news of the month.

STI rates have been growing significantly in the United States and around the world. To fix the problem, we need a renewed focus on this therapeutic area, according to top public health officials.

According to results from the Rwanda Population-based HIV Impact Assessment (RPHIA), 76% of all adults living with HIV in Rwanda have achieved viral load suppression.

Investigators used national electronic health record data to determine the proportion of American adults who have been tested for HIV.

Amid growing reports of viral resistance in patients living with HIV, IDSA, HIV Medicine Association, and American Academy of HIV Medicine have issued a joint policy paper.

Jump-starting HIV treatment in hospital emergency department settings could be a key to curbing the spread of the virus.

The approval allows treatment-experienced adults living with HIV who are virally suppressed to switch to doravirine or doravirine/lamivudine/tenofovir disoproxil fumarate.

Along with other heart ailments, new research finds that people living with HIV have a greater risk of atrial fibrillation.

The SLATE study evaluated whether a clinical algorithm can help clinicians determine eligibility for same-day treatment among people living with HIV and initiate ART when appropriate.

People are living long lives with HIV care, but it is important to acknowledge aging-related challenges of HIV prevention, testing, treatment, and care.

The prevalence of sexually transmitted infections is rising, and a new study suggests a higher risk for HIV-positive MSM whose partners use PrEP.

A study conducted in Kenya demonstrated that appealing to women who present at family-planning clinics to obtain birth control can increase the percentage who will use PrEP.

There was no difference in HIV acquisition among women who used progestogen-only injectables, implants, or intrauterine devices.

In 2018, the UK recorded 4484 new cases of HIV, representing a 28% decrease compared with the 6271 new diagnoses documented in 2015.

That daily PrEP dose may not be necessary, according to a new study that examined time-driven and event-driven dosing in a high-risk population.

Cryptococcal meningitis is the leading cause of mortality in people living with HIV/AIDS, but a new study shows promising results for alternative treatments.

As the summer comes to a close, our editorial team is looking back at the top FDA approvals of 2019 to date and looking ahead at what is left on the docket this year.

Allowing pharmacists to provide PrEP care is a feasible alternative for improving access to the treatment, according to a recent trial that was well-received by patients and pharmacists.